Networking Support Call (NSC2025) - Translational aspects of Personalised Medicine
Quick Facts
Email me updates on this grant
Get notified about:
- Deadline changes
- New FAQs & guidance
- Call reopened
- Q&A webinars
We'll only email you about this specific grant. Unsubscribe anytime. No spam.
Ready to Apply?
Get a personalized assessment of your eligibility and application strategy
See in 5 min if you're eligible for Networking Support Call (NSC2025) - Translational aspects of Personalised Medicine offering max €70.3M funding💰 Funding Details
Funding Description
What the NSC2025 Call Funds
* Coordination & Support Actions (CSA) that build or expand trans-national networks accelerating the translation of Personalised Medicine (PM) research results into clinical practice.
* Activities may include:
* Joint workshops, conferences and brokerage events.
* Thematic working groups producing harmonised protocols, clinical pathways or data standards.
* Short-term staff exchanges, twinning & mentoring schemes between research, clinical and industrial partners.
* Development of FAIR data infrastructures or registries focused on PM biomarkers and patient stratification.
* Stakeholder engagement (patients, regulators, HTA bodies) and policy uptake actions.
Financial Parameters
* Total call budget: up to €70,349,525 (indicative, subject to EU 2025 work-programme adoption).
* EU contribution per project: typically €2–6 million. Larger envelopes possible for consortia that convincingly justify pan-European scale.
* Funding rate: 100 % of eligible direct costs + 25 % flat-rate for indirect costs (Horizon Europe CSA rules).
* Cascade funding: Beneficiaries may allocate up to 20 % of their EU grant to third parties (open calls, travel grants, hackathons, etc.).
* Project duration: 24–48 months.
* No requirement for own co-funding beyond in-kind commitments.
Eligibility Snapshot
* Minimum consortium: 3 independent legal entities from 3 different EU Member States or Horizon Europe Associated Countries.
* Eligible entities: universities, research organisations, SMEs, large industry, hospitals, patient organisations, public authorities.
* Gender Equality Plan mandatory for public bodies, higher education establishments & research orgs.
* Ethical compliance with GDPR, clinical studies legislation (if applicable) and Horizon Europe ethics framework.
Timeline (indicative)
* Call opening: Q4 2024
* Proposal deadline: Q1 2025 (single-stage submission)
* Evaluation results: Q2 2025
* Grant preparation & signature: Q3 2025
* Project start: no later than Q4 2025
Key Contact & Resources
* Funding & Tenders Portal call page (search "HORIZON-HLTH-2023-CARE-08-01")
* National Contact Points (NCPs) for Health
* EU Helpdesk for cascade funding rules
📊 At a Glance
Get Grant Updates
Get notified about:
- Deadline changes
- New FAQs & guidance
- Call reopened
- Q&A webinars
We'll only email you about this specific grant. Unsubscribe anytime. No spam.
🇪🇺 Strategic Advantages
EU-Wide Advantages & Opportunities for "Networking Support Call (NSC2025) – Translational aspects of Personalised Medicine"
1. Pan-European Critical Mass
- Access to 27 national health systems supplies the large, heterogenous patient cohorts required to validate personalised-medicine (PM) tools that would be statistically impossible in a single country.
- Pooling of >3 000 university hospitals & research institutes accelerates recruitment, biobanking and longitudinal studies, reducing time-to-market for PM diagnostics and therapies.
2. Harmonised Standards & Interoperability
- EU-level coordination allows early alignment with EMA, ECDC and HTA bodies, smoothing regulatory uptake of PM innovations.
- Cross-border projects can pilot European Health Data Space (EHDS) standards for genomic & real-world data exchange, ensuring solutions are “EHDS-ready” upon commercialisation.
3. Synergy with Existing EU Assets
- Leverage 1 300+ nodes of the European Reference Networks (ERNs) to obtain rare-disease expertise and sample access.
- Integrate with Digital Europe & EuroHPC infrastructures for high-performance computing of multi-omics datasets.
- Combine funding with EU4Health, EIT Health & COST Actions for training, SME acceleration and policy dissemination.
4. Cascade Funding as Innovation Booster
- The NSC2025 cascade model lets consortia issue rapid micro-grants (≈€60-150 k) to start-ups and clinics for pilot studies, lowering entry barriers and diversifying the innovation pipeline.
- Facilitates East-West & North-South inclusion by financing smaller, high-potential actors that under traditional calls lack resources to join.
5. Economies of Scale in Clinical Translation
- Joint procurement of AI/NGS platforms, certified biobanking, GMP facilities cuts per-unit costs by 20-40 % compared with national purchases.
- Shared ethical & legal advisory boards minimize duplication and legal fees, freeing ~10 % of project budgets for science.
6. Strengthened Market Uptake & Competitiveness
- A validated PM solution under an EU-wide study gains immediate credibility in a €450 bn health-care market, facilitating CE-marking and payer acceptance.
- Positions EU companies to compete globally against US & Asian PM giants, anchoring IP and high-value jobs in Europe.
7. Policy & Societal Impact
- Supports European Beating Cancer Plan and Rare-Disease Policy by translating stratified therapies faster.
- Generates actionable evidence for value-based healthcare models, informing national reimbursement schemes.
8. Long-Term Sustainability
- Networks created under NSC2025 can evolve into European Innovation Ecosystems for PM, eligible for future Horizon Europe, Interregional Innovation Investments (I3) and Cohesion Policy funds.
- Data and governance models developed become blueprints for Member State implementation, ensuring lasting impact beyond the grant lifetime.
🏷️ Keywords
Ready to Apply?
Get a personalized assessment of your eligibility and application strategy
See in 5 min if you're eligible for Networking Support Call (NSC2025) - Translational aspects of Personalised Medicine offering max €70.3M funding